Sienna Biopharmaceuticals, Inc. buys Creabilis plc and with it SNA-120, formerly CT327 and SNA-125, formerly CT340.

Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage medical dermatology and aesthetics company, announced it has acquired Creabilis plc, a privately held specialty pharmaceutical company focused on developing first-in-class topical treatments for common inflammatory skin conditions, including psoriasis, atopic dermatitis and pruritus (itch). Under the terms of the agreement, Sienna will make an undisclosed upfront payment in cash and stock, as well as additional payments contingent upon achieving specific regulatory and commercial milestones, which could exceed $150 million in aggregate. Additional terms were not disclosed. Sienna has acquired first-in-class late-stage and patented clinical candidates, including: A Phase IIb topical tropomyosin receptor kinase A (TrkA) inhibitor (SNA-120, formerly CT327) for the treatment of pruritus and psoriasis. A topical TrkA/janus kinase 3 (JAK3) inhibitor (SNA-125, formerly CT340) for the treatment of inflammatory skin conditions, including atopic dermatitis, psoriasis and pruritus. These new drug candidates were generated through a proprietary �Topical by Design� platform technology developed by Creabilis that provides localized efficacy and limited systemic exposure. Sienna also acquired a portfolio of pre-clinical drug candidates generated by this technology.